BioCentury | Jun 27, 2019
Distillery Therapeutics

An insulin-conjugated dual SLC2A1/SLC2A4 inhibitor for diabetes

...glucose conditions. Under high blood glucose conditions, the conjugate dissociates from the transporters and activates INSR...
...insulin. TARGET/MARKER/PATHWAY: Solute carrier family 2 facilitated glucose transporter member 1 (SLC2A1; GLUT1); SLC2A4 (GLUT4); insulin receptor (INSR)...
...Gu, University of California Los Angeles, Los Angeles, Calif. email: guzhen@ucla.edu Hongjiang Li University of California Los Angeles Insulin receptor (INSR) Solute...
BioCentury | Aug 29, 2018
Distillery Therapeutics

Musculoskeletal

...DM1 patient, miR-23b and miR-218 antagomirs decreased disease-associated splicing defects in bridging integrator 1 (BIN1), insulin receptor (INSR)...
BioCentury | Jul 10, 2018
Distillery Therapeutics

Endocrine/Metabolic

...expression. In white adipose tissue from the model, FST knockdown plus insulin increased phosphorylation of insulin receptor...
...substrate 1 (IRS1) and protein kinase B (AKT; AKT1; PKB; PKBA) at sites associated with insulin receptor...
...2018 doi:10.1038/s41591-018-0048-0 CONTACT: Morris White, Harvard Medical School, Boston, Mass. email: morris.white@childrens.harvard.edu Allison Johnson Harvard Medical School Follistatin (FST) Insulin receptor...
BioCentury | May 1, 2018
Distillery Therapeutics

Cancer

...identifying and testing dual inhibitors of IRS1 and IRS2 in models of KRAS-mutant NSCLC. TARGET/MARKER/PATHWAY: Insulin receptor...
...Nada Kalaany, Harvard Medical School, Boston, Mass. email: nada.kalaany@childrens.harvard.edu Elizabeth S. Eaton Harvard Medical School Insulin receptor substrate 1 (IRS1) Insulin receptor...
BioCentury | Apr 27, 2018
Company News

Sanofi's Dupixent misses sales estimates, Regeneron slips

...REGN668 (Compound #), dupilumab (Generic), Dupixent (Informal) Lantus XR, Toujeo, insulin glargine (u300) Lantus, insulin glargine Regeneron Pharmaceuticals Inc. Sanofi Insulin receptor (INSR) Interleukin-13...
BioCentury | Mar 9, 2018
Clinical News

ArmaGen reports 52-week Phase II data for MPS I candidate

...The enzyme replacement therapy consisting of alpha-L-iduronidase (IDUA) fused to an IgG antibody targeting the insulin receptor (INSR)...
...Insulin receptor (INSR) Description: Enzyme replacement therapy consisting of alpha-L-iduronidase (IDUA) fused to an IgG antibody targeting INSR...
...measured by forced vital capacity (FVC) Status: Additional Phase I/II data Milestone: NA Jaime De Leon AGT-181 HIRMAb-IDUA ArmaGen Inc. Insulin receptor (INSR) WORLDSymposium...
BioCentury | Oct 27, 2017
Company News

Biocon, JDRF in deal for insulin tregopil study

...Ltd. (NSE:BIOCON; BSE:BIOCON), Bangalore, India JDRF , New York, N.Y. Business: Endocrine/Metabolic Chris Lieu insulin aspart Insulin tregopil NovoLog Biocon Ltd. JDRF Insulin receptor (INSR)...
BioCentury | Sep 1, 2017
Company News

Xoma, Novartis partner for IL-1 beta mAbs and related IP

...hypoglycemia following bariatric surgery. XOMA 358 is a negative allosteric IgG2 mAb that binds to insulin receptor (INSR)...
...AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Cardiovascular, Antibodies Jaime De Leon ACZ885 canakinumab gevokizumab Ilaris S 78989 XOMA 052 XOMA 089 XOMA 358 Novartis AG Servier Xoma Corp. Insulin receptor (INSR) Interleukin-1...
BioCentury | Aug 25, 2017
Company News

Xoma gains on Novartis IL-1 beta mAb deals

...hypoglycemia following bariatric surgery. XOMA 358 is a negative allosteric IgG2 mAb that binds to insulin receptor (INSR)...
BioCentury | Jul 28, 2017
Clinical News

Adocia begins head-to-head trial of BioChaperone Lispro vs. Fiasp and Novolog

...Fiasp and Novolog. Adocia S.A. (Euronext:ADOC), Lyon, France Product: BioChaperone Lispro Business: Endocrine/Metabolic Molecular target: Insulin receptor (INSR)...
...started Milestone: Phase II data (year end 2017) Alex Himes BioChaperone Lispro FIAsp NovoLog Adocia S.A. Eli Lilly and Co. Novo Nordisk A/S Insulin receptor (INSR)...
Items per page:
1 - 10 of 440